Chromatin-associated regulation of HIV-1 transcription: Implications for the development of therapeutic strategies

Subcellular Biochemistry

Volumn 41, Issue , 2007, Pages 371-396

  Quivy, Vincent ^a   de Walque, Stephane ^a   van Lint, And Carine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYRIBONUCLEASE I; ENZYME INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; TRANSACTIVATOR PROTEIN;

ACETYLATION; ANIMAL; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; METABOLISM; NUCLEOSOME; PROTEIN PROCESSING; REVIEW; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY;

ACETYLATION; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-HIV AGENTS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEOXYRIBONUCLEASE I; ENZYME INHIBITORS; GENE PRODUCTS, TAT; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; NUCLEOSOMES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC; VIRUS INTEGRATION; VIRUS LATENCY;

EID: 34249802347     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (147)

1. Adam E, Quivy V, Bex F, Chariot A, Collette Y, Vanhulle C, Schoonbroodt S, Goffin V, Nguyên TL-A, Carrard G, Friguet B, de Launoit Y, Burny A, Bours V, Piette J, Van Lint C (2003) Potentiation of TNFα-induced NF-kappaB activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearence of I-Balpha. Mol Cell Biol 23: 6200-6209.
2. al Harthi L, Roebuck KA (1998) Human immunodeficiency virus type-1 transcription: role of the 5'-untranslated leader region. Int J Mol Med 1: 875-881.
3. Aoyagi S, Hayes JJ (2002) hSWI/SNF-catalyzed nucleosome sliding does not occur solely via a twistdiffusion mechanism. Mol Cell Biol 22: 7484-7490.
4. Barboric M, Peterlin BM (2005) A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLoS Biol 3: 200-203.
5. Bennasser Y, Le SY, Benkirane M, Jeang, KT (2005) Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 22: 607-619.
6. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, Brown S, Margolis LB, Hirsch I (2004) Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78: 10507-10515.
7. Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, Wang XF, Rudkin BB (1999) Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene 18: 2872-2882.
8. Bisgrove D, Lewinski M, Bushman F, Verdin E (2005) Molecular mechanisms of HIV-1 proviral latency. Expert Rev Anti Infect Ther 3: 805-814.
9. Blankson JN, Persaud D, Siliciano RF (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53: 557-593.
10. Bourgeois CF, Kim YK, Churcher MJ, West MJ, Karn J (2002) Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences. Mol Cell Biol 22: 1079-1093.
11. Brady J, Kashanchi F (2005) Tat gets the "green" light on transcription initiation. Retrovirology 2.
12. Bres V, Tagami H, Peloponese JM, Loret E, Jeang KT, Nakatani Y, Emiliani S, Benkirane M, Kiernan RE (2002) Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J 21: 6811-6819.
13. Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Treand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M (2003) A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 5: 754-761.
14. Bres V, Gomes N, Pickle L, Jones KA (2005) A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat. Genes Dev 19: 1211-1226.
15. Brigati C, Giacca M, Noonan DM, Albini A (2003) HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol Lett 220: 57-65.
16. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705.
17. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR (1999) Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94: 1401-1408.
18. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS (1997a) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94: 13193-13197.
19. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF (1997b) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
20. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS (1998) Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188: 83-91.
21. Col E, Caron C, Seigneurin-Berny D, Gracia J, Favier A, Khochbin S, (2001) The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem 276: 28179-28184.
22. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85: 43-49.
23. Collman RG, Perno CF, Crowe SM, Stevenson M, Montaner LJ (2003) HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol 74: 631-634.
24. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM (2000) The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74: 6790-6799.
25. Coull JJ, He G, Melander C, Rucker VC, Dervan PB, Margolis DM (2002) Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol 76: 12349-12354.
26. Craig JM (2005) Heterochromatin-many flavours, common themes. Bioessays 27: 17-28.
27. Crazzolara R, Johrer K, Johnstone RW, Greil R, Kofler R, Meister B, Bernhard D (2002) Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 119: 965-969.
28. de la Serma I, OhkawaY, Imbalzano AN (2006) Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 7: 461-473.
29. Demonté D, Quivy V, Colette Y, Van Lint C (2004) Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 68: 1231-1238.
30. Deng L, de la Fuente C, Fu P, Wang L, Donnelly R, Wade JD, Lambert P, Li H, Lee CG, Kashanchi F (2000) Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277: 278-295.
31. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C (1999) Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19: 5504-5511.
32. Dorr A, Kiermer V, Pedal A, Rackwitz HR, Henklein P, Schubert U, Zhou MM, Verdin E, Ott M (2002) Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J 21: 2715-2723.
33. Dover GJ, Brusilow S, Charache S (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84: 339-343.
34. El Kharroubi A, Martin MA (1996) cis-acting sequences located downstream of the human immunodeficiency virus type 1 promoter affect its chromatin structure and transcriptional activity. Mol Cell Biol 16: 2958-2966.
35. El Kharroubi A, Piras G, Zensen R, Martin MA (1998) Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 18: 2535-2544.
36. Erselius JR, Jostes B, Hatzopoulos AK, Mosthaf L, Gruss P (1990) Cell-type-specific control elements of the lymphotropic papovavirus enhancer. J Virol 64: 1657-1666.
37. Felsenfeld G, Groudine M (2003) Controlling the double helix. Nature 421: 448-453.
38. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
39. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
40. Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15: 172-183.
41. Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM (2004) Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol 24: 787-795.
42. Goffin V, Demonte D, Vanhulle C, de Walque S, de Launoit Y, Burny A, Collette Y, Van Lint C (2005) Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. Nucleic Acids Res 33: 4285-4310.
43. Gordon S, Akopyan G, Garban H, Bonavida B (2006) Transcription factor YY1: structure, function and therapeutic implications in cancer biology. Oncogene 25: 1125-1142.
44. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, Pierson TC, Margolick JB, Siliciano RF, Siliciano JD (2004) Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 78: 6122-6133.
45. Hansen JC (2002) Conformational dynamics of the chromatin fiber in solution: determinants, mechanisms, and functions. Annu Rev Biophys Biomol Struct 31: 361-392.
46. Hassan AH, Prochasson P, Neely KE, Galasinski SC, Chandy M, Carrozza MJ, Workman JL (2002) Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell 111: 369-379.
47. He G, Margolis DM (2002) Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 22: 2965-2973.
48. Henderson AJ, Calame KL (1997) CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4+ T cells. Proc Natl Acad Sci USA 94: 8714-8719.
49. Henderson A, Bunce M, Siddon N, Reeves R, Tremethick DJ (2000) High-mobility-group protein I can modulate binding of transcription factors to the U5 region of the human immunodeficiency virus type 1 proviral promoter. J Virol 74: 10523-10534.
50. Henderson A, Holloway A, Reeves R, Tremethick DJ (2004) Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol Cell Biol 24: 389-397.
51. Hines R, Sorensen BR, Shea MA, Maury W (2004) PU. 1 binding to ets motifs within the equine infectious anemia virus long terminal repeat (LTR) enhancer: regulation of LTR activity and virus replication in macrophages. J Virol 78: 3407-3418.
52. Hsia SC, Shi YB (2002) Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor. Mol Cell Biol 22: 4043-4052.
53. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1991) Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253: 71-74.
54. Imai K, Okamoto T (2006) Transcriptional repression of Human Immunodeficiency Virus Type 1 by AP-4. J Biol Chem 281: 12495-12505.
55. Jennings HR, Romanelli F (1999) The use of valproic acid in HIV-positive patients. Ann Pharmacother 33: 1113-1116.
56. Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37: 103-110.
57. Jordan A, Defechereux P, Verdin E (2001) The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 20: 1726-1738.
58. Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877.
59. Kamine J, Chinnadurai G (1992) Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1. J Virol 66: 3932-3936.
60. Kiefer HL, Hanley TM, Marcello JE, Karthik AG, Viglianti GA (2004) Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter. Uncoupling of histone acetylation and chromatin remodeling. J Biol Chem 279: 43604-43613.
61. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C (1999) HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 18: 6106-6118.
62. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76: 8118-8123.
63. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, Pomerantz RJ (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015.
64. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF (2004) The multifactorial nature of HIV-1 latency. Trends Mol Med 10: 525-531.
65. Lee ES, Sarma D, Zhou H, Henderson AJ (2002) CCAAT/enhancer binding proteins are not required for HIV-1 entry but regulate proviral transcription by recruiting coactivators to the long-terminal repeat in monocytic cells. Virology 299: 20-31.
66. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM (2005) Depletion of latent HIV-1 infection in vivo: a proof of concept study. Lancet 366: 523-524.
67. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli S, Verdin E, Berry CC, Ecker JR, Bushman FD (2005) Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol 79: 6610-6619.
68. Lusic M, Marcello A, Cereseto A, Giacca M (2003) Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 22: 6550-6561.
69. Marcello A (2006) Latency: the hidden HIV-1 challenge. Retrovirology 3: 7.
70. Marecki S, McCarthy KM, Nikolajczyk BS (2004) PU. 1 as a chromatin accessibility factor for immunoglobulin genes. Mol Immunol 40: 723-731.
71. Margueron R, Trojer P, Reinberg D (2005) The key to development: interpreting the histone code? Curr Opin Genet Dev 15: 163-176.
72. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483.
73. Martens JA, Winston F (2003) Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr Opin Genet Dev 13: 136-142.
74. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, Maki RA (1996) Targeted disruption of the PU. 1 gene results in multiple hematopoietic abnormalities. EMBO J 15: 5647-5658.
75. Mclean AR, Michie CA (1995) In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 92: 3707-3711.
76. Michie CA, McLean A, Alcock C, Beverley PC (1992) Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360: 264-265.
77. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
78. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou MM (2002) Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 9: 575-586.
79. Nahreini P, Mathews MB (1997) Transduction of the human immunodeficiency virus type 1 promoter into human chromosomal DNA by adeno-associated virus: effects on promoter activity. Virology 234: 42-50.
80. Nakatani Y (2002) HIV-1 transcription: activation mediated by acetylation of Tat. Structure 10: 443-444.
81. Narlikar GJ, Phelan ML, Kingston RE (2001) Generation and interconversion of multiple distinct nucleosomal states as a mechanism for catalyzing chromatin fluidity. Mol Cell 8: 1219-1230.
82. Narlikar GJ, Fan HY, Kingston RE (2002) Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487.
83. Navikas V, Link J, Persson C, Olsson T, Hojeberg B, Ljungdahl A, Link H, Wahren B (1995) Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 9: 484-489.
84. Nelsen B, Tian G, Erman B, Gregoire J, Maki R, Graves B, Sen R (1993) Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins. Science 261: 82-86.
85. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, Idler K, Zack JA, Chen IS (1990) HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348: 69-73.
86. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E (1999) Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 9: 1489-1492.
87. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney MW, Hruby, H., Jung, M., Verdin, E., and Ott, M. 2005. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS. Biol. 3: e41.
88. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ (2000) A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 28: 663-668.
89. Persaud D, Zhou Y, Siliciano JM, Siliciano RF (2003) Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 77: 1659-1665.
90. Peterson CL, Workman JL (2000) Promoter targeting and chromatin remodeling by the SWI/SNF complex. Curr Opin Genet Dev 10: 187-192.
91. Peterson CL, Laniel MA (2004) Histones and histone modifications. Curr Biol 14: R546-R551.
92. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
93. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868.
94. Pierson T, McArthur J, Siliciano RF (2000) Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18: 665-708.
95. Ping YH, Rana, TM (2001) DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem 276: 12951-12958.
96. Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, Atchison ML (1992) PU. 1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3' enhancer activity. Mol Cell Biol 12: 368-378.
97. Price DH (2000) P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20: 2629-2634.
98. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, Berkhout B, Castellano R, de Launoit Y, Burny A, Piette J, Bours V, Van Lint C (2002) Synergistic activation of HIV-1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 76: 11091-11103.
99. Quivy V, Van Lint C (2002) Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system. Biochem Pharmacol 64: 925-934.
100. Quivy V, Van Lint C (2004) Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 68: 1221-1229.
101. Rabbi MF, Saifuddin M, Gu DS, Kagnoff MF, Roebuck KA (1997) U5 region of the human immunodeficiency virus type 1 long terminal repeat contains TRE-like cAMP-responsive elements that bind both AP-1 and CREB/ATF proteins. Virology 233: 235-245.
102. Rabson AB, Lin HC (2000) NF-kappa B and HIV: linking viral and immune activation. Adv Pharmacol 48: 161-207.
103. Raha T, Cheng SW, Green MR (2005) HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol 3: e44.
104. Roebuck KA, Saifuddin M (1999) Regulation of HIV-1 transcription. Gene Expr 8: 67-84.
105. Rohr O, Marban C, Aunis D, Schaeffer E (2003) Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 74: 736-749.
106. Romanelli F, Pomeroy C (2003) Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm Des 9: 1433-1439.
107. Romerio F, Gabriel MN, Margolis DM (1997) Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol 71: 9375-9382.
108. Saha A, Wittmeyer J, Cairns BR (2002) Chromatin remodeling by RSC involves ATP-dependent DNA translocation. Genes Dev 16: 2120-2134.
109. Schrager LK, D'Souza MP (1998) Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280: 67-71.
110. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
111. Scott EW, Simon MC, Anastasi J, Singh H (1994) Requirement of transcription factor PU. 1 in the development of multiple hematopoietic lineages. Science 265: 1573-1577.
112. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA (2002) Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76: 13077-13082.
113. Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, Nappi F, Marsili G, Marziali G, Coccia EM, Ensoli B, Battistini A (2002) Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 195: 1359-1370.
114. Sheridan PL, Mayall TP, Verdin E, Jones KA (1997) Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 11: 3327-3340.
115. Shioda T, Levy JA, Cheng-Mayer C (1991) Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349: 167-169.
116. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
117. Sims RJ, Belotserkovskaya R, Reinberg D (2004) Elongation by RNA polymerase II: the short and long of it. Genes Dev 18: 2437-2468.
118. Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, Odum N (2003) Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 101: 1430-1438.
119. Smithgall MD, Wong JG, Critchett KE, Haffar OK (1996) IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 156: 2324-2330.
120. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T (1997) Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150.
121. Steger DJ, Eberharter A, John S, Grant PA, Workman JL (1998) Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. Proc Natl Acad Sci USA 95: 12924-12929.
122. Sune C, Garcia-Blanco MA (1995) Sp1 transcription factor is required for in vitro basal and Tatactivated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol 69: 6572-6576.
123. Suzuki T, Kimura A, Nagai R, HorikoshiM(2000) Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells 5: 29-41.
124. Thierry S, Marechal V, Rosenzwajg M, Sabbah M, Redeuilh G, Nicolas JC, Gozlan J (2004) Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. J Virol 78: 12198-12206.
125. Tréand C, du Chêne I, Bres V, Kiernan R, Benarous R, Benkirane M, Emiliani S (2006) Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J 25: 1690-1699.
126. Tunnicliff G (1999) Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 50: 347-365.
127. Van Lint C, Ghysdael J, Paras P Jr, Burny A, Verdin E (1994) A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1. J Virol 68: 2632-2648.
128. Van Lint C, Emiliani S, Ott M, Verdin E (1996a) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15: 1112-1120.
129. Van Lint C, Emiliani S, Verdin E (1996b) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-53.
130. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E (1997) Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 71: 6113-6127.
131. Van Lint C, (2000) Role of chromatin in HIV-1 transcriptional regulation. Adv Pharmacol 48: 121-160.
132. Verdin E (1991) DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol 65: 6790-6799.
133. Verdin E, Paras P Jr, Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12: 3249-3259.
134. West MJ, Lowe AD, Karn J (2001) Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 75: 8524-8537.
135. Williams SA, Greene WC (2005) Host factors regulating post-integration latency of HIV. Trends Microbiol 13: 137-139.
136. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25: 139-149.
137. Wolffe A (1999) Chromatin: Structure and Function. Academic Press, San Diego, CA.
138. Wolffe AP (2001) Transcriptional regulation in the context of chromatin structure. Essays Biochem 37: 45-57.
139. Wong MC, Suite ND, Labar DR (1990) Seizures in human immunodeficiency virus infection. Arch Neurol 47: 640-642.
140. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
141. Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67: 545-579.
142. Wu X, Li Y, Crise B, Burgess SM (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
143. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H (1999) NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 97: 41-51.
144. Yedavalli VS, Benkirane M, Jeang KT (2003) Tat and trans-activation-responsive (TAR) RNAindependent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 278: 6404-6410.
145. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18: 1101-1108.
146. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discovery 5: 37-50.
147. Xiao H, Hasegawa T, Isobe K (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: 1371-1376.